Piper Sandler Has Lowered Expectations for Collegium Pharmaceutical (NASDAQ:COLL) Stock Price

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective dropped by equities researchers at Piper Sandler from $37.00 to $36.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the specialty pharmaceutical company’s stock. Piper Sandler’s price target suggests a potential upside of 17.23% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $30.71 on Tuesday. The stock’s 50-day simple moving average is $31.03 and its two-hundred day simple moving average is $34.14. Collegium Pharmaceutical has a twelve month low of $28.39 and a twelve month high of $42.29. The firm has a market capitalization of $990.40 million, a P/E ratio of 13.24 and a beta of 0.82. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 3.98% of the stock is owned by insiders.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC increased its stake in shares of Collegium Pharmaceutical by 57.1% in the second quarter. Millennium Management LLC now owns 303,870 shares of the specialty pharmaceutical company’s stock worth $9,785,000 after buying an additional 110,499 shares during the period. Sanctuary Advisors LLC bought a new stake in Collegium Pharmaceutical in the 2nd quarter worth $523,000. SG Americas Securities LLC increased its position in shares of Collegium Pharmaceutical by 8.7% in the third quarter. SG Americas Securities LLC now owns 18,285 shares of the specialty pharmaceutical company’s stock valued at $707,000 after acquiring an additional 1,470 shares during the period. GAMMA Investing LLC raised its stake in shares of Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 792 shares during the last quarter. Finally, CWM LLC boosted its holdings in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.